Leigh MacMillan

Eric Kandel, M.D., who was awarded the Nobel Prize in 2000 for discovering molecular mechanisms of memory storage, told the crowd at last week’s Flexner Discovery Lecture that he has recently become interested in memory in the aging brain. Read More

Vanderbilt investigators have identified novel regulators of insulin-producing beta-cell proliferation and survival, suggesting new targets for the treatment of type 2 diabetes. Read More

Two brain signaling pathways have overlapping functions in regulating anxiety, suggesting that therapeutics aimed at one or the other will impact both. Read More

Nobel laureate Eric R. Kandel, M.D., renowned for his studies of learning and memory, will give the next Flexner Discovery Lecture on Thursday, May 4. Read More

A new protein structure may guide the development of Alzheimer's therapeutics. Read More

Structural details of a protein that removes DNA lesions shed light on fundamental mechanisms of DNA repair. Read More

A detailed structural and functional analysis of the yeast protein that is the main target of antifungal drugs will help direct efforts to develop better treatments. Read More

James Spudich, Ph.D., renowned for his studies of proteins that function as molecular motors, will deliver the next Flexner Discovery Lecture on Thursday, April 6. Read More

An inhibitor of cell metabolism may be a good therapeutic target for neuroblastoma, which accounts for about 15 percent of pediatric cancer-related deaths. Read More

A higher abundance of certain bacterial species in the mouth appears to reduce the risk of type 2 diabetes, Vanderbilt investigators have discovered. Read More

Routine use of hydroxocobalamin should be considered for victims of smoke inhalation, Vanderbilt researchers suggest. Read More

Paul Bieniasz, Ph.D., a pioneer in the study of retroviruses, will deliver the next Flexner Discovery Lecture on Thursday, March 9. Read More

Vanderbilt researchers hope their new method to describe cells will be widely adopted and used to generate a “Who’s Who” database of cell types. Read More

The protein beta-catenin may be a good target for therapies to treat lung disease that is a common complication of preterm birth. Read More

A signaling protein overexpressed in upper gastrointestinal cancers is an attractive therapeutic target. Read More

Josep Dalmau, M.D., Ph.D., renowned for his studies of immune disorders affecting the brain and spinal cord, will deliver the next Flexner Discovery Lecture on Thursday, Feb. 23. Read More

The signaling molecule IL-15 promotes septic shock, a life-threatening condition involving organ injury caused by infection. Read More

Vanderbilt researchers have identified a unique example of communication between bacterial signaling systems, which may have relevance for antibiotic resistance. Read More

High dose flu vaccine boosts the immune response in older adults by increasing activation of certain immune cells. Read More

Although cancers arising from different areas of the large intestine are heterogeneous, they appear to use similar important tumorigenic pathways. Read More